# EDGAR Filing Document

**Accession Number:** 0001042418
**File Stem:** 0000000000-25-009975
**Filing Date:** 2025-9
**Character Count:** 2230
**Document Hash:** 90baafe2145f1c3e11fcfc9e9727f541
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-009975.hdr.sgml**: 20260122

**ACCESSION NUMBER**: 0000000000-25-009975

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250915

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Inhibitor Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001042418
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 541641133
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 001-13467

**BUSINESS ADDRESS:**
- **STREET 1:** 4830 W. KENNEDY BLVD.
- **STREET 2:** SUITE 600
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33609
- **BUSINESS PHONE:** (813) 766-2462

**MAIL ADDRESS:**
- **STREET 1:** 4830 W. KENNEDY BLVD.
- **STREET 2:** SUITE 600
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33609

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HedgePath Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20130816

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** COMMONWEALTH BIOTECHNOLOGIES INC
- **DATE OF NAME CHANGE:** 19970714
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001641172-25-001190

## Text-Extract

```

                                                        September 15, 2025

James A. McNulty
Interim Chief Financial Officer
Inhibitor Therapeutics, Inc.
3014 W. Palmira Avenue
Suite 302
Tampa, FL 33629

        Re: Inhibitor Therapeutics, Inc.
            Form 10-K for the Year Ended December 31, 2024
            Filed March 28, 2025
            File No. 001-13467
Dear James A. McNulty:

       We have completed our review of your filing. We remind you that the
company and
its management are responsible for the accuracy and adequacy of their
disclosures,
notwithstanding any review, comments, action or absence of action by the staff.

                                                        Sincerely,

                                                        Division of Corporation
Finance
                                                        Office of Life Sciences

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._